A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
NCT06043700
Recruiting
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
11/21/2023
Locations: Eisai Site #1, Lady Lake, Florida +1 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071
Recruiting
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
11/16/2023
Locations: Xenoscience Inc., Phoenix, Arizona +196 locations
Conditions: Alzheimer's Disease
Register for Updates
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT05744401
Recruiting
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
11/01/2023
Locations: Charter Research, Lady Lake, Florida +18 locations
Conditions: Alzheimer's Disease
Register for Updates
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757
Recruiting
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Register for Updates
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
NCT02792257
Recruiting
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the AD course. One of the most troubling of these symptoms is agitation (Agit-AD), typified by a variety of problem behaviors including combativeness, yelling, pacing, lack of cooperation with care, insomnia, and restlessness. There is a great need for better interventions... Read More
Gender:
All
Ages:
Between 60 years and 95 years
Trial Updated:
10/23/2023
Locations: Miami Jewish Health, Miami, Florida +4 locations
Conditions: Alzheimer's Disease
Register for Updates
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
10/21/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease
Register for Updates
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
NCT05804383
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/18/2023
Locations: Yale University, New Haven, Connecticut +1 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
NCT05619692
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/17/2023
Locations: Sage Investigational Site, Gilbert, Arizona +35 locations
Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Register for Updates
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
10/16/2023
Locations: MD First Research - Chandler, Chandler, Arizona +73 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
10/10/2023
Locations: MD First Research - Chandler, Chandler, Arizona +46 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Register for Updates
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
NCT05655195
Recruiting
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the... Read More
Gender:
All
Ages:
Between 50 years and 100 years
Trial Updated:
09/26/2023
Locations: Massachusetts Institute of Technology, Cambridge, Massachusetts
Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Register for Updates
Retinal Imaging in Neurodegenerative Disease
NCT03233646
Recruiting
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Mild Cognitive Impairment, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease, Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Normal Cognition
Register for Updates